ACM
VRTX icon

Atika Capital Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Atika Capital Management’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Hold
0
– -$7.45M – 107
2019
Q4 		– Hold
0
– – – 30

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Atika Capital Management's VRTX Position: Q3 2024 in Review

Atika Capital Management sold out of Vertex Pharmaceuticals (VRTX) in Q3 2024, closing a stake of 13,000 shares — an estimated $6.09M sold.

Atika Capital Management first reported a position in VRTX in Q3 2014 and held it in 10 quarters. The position peaked at $6.09M in Q2 2024. 1,545 funds tracked by Wall St. Rank hold VRTX as of Q3 2024.

  • Atika Capital Management reported no remaining Vertex Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Atika Capital Management sold 13,000 Vertex Pharmaceuticals shares in Q3 2024, an estimated $6.09M.
  • Atika Capital Management first reported a position in Vertex Pharmaceuticals in Q3 2014 and held it in 10 quarters.
  • Atika Capital Management's Vertex Pharmaceuticals position peaked at $6.09M in Q2 2024.
  • 1,545 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2024.

Based on Atika Capital Management's 13F filing for Q3 2024, filed 13 Nov 2024.